Evidence map›Paper›PMID 41514664›Full record

ReviewCancers2026

Targeting the MAPK Pathway in Brain Tumors: Mechanisms and Therapeutic Opportunities.

Dimitrios Vrachas, Elisavet Kosma, Angeliki-Ioanna Giannopoulou, Angeliki Margoni, Antonios N Gargalionis, Elias A El-Habr, Christina Piperi, Christos Adamopoulos

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Non-Meningothelial Mesenchymal Tumor of the Central Nervous System: Case Report and Literature Review.Neuropathology : official journal of the Japanese Society of Neuropathology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Dimitrios VrachasDepartment of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Elisavet KosmaDepartment of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Angeliki-Ioanna GiannopoulouDepartment of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Angeliki MargoniDepartment of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.ORCID 0009-0007-0798-6262
Antonios N GargalionisLaboratory of Clinical Biochemistry, Medical School, 'Attikon' University General Hospital, National and Kapodistrian University of Athens, 12462 Athens, Greece.ORCID 0000-0003-4332-6409
Elias A El-HabrDepartment of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.ORCID 0000-0002-4531-9707
Christina PiperiDepartment of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.ORCID 0000-0002-2701-0618
Christos AdamopoulosDepartment of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.ORCID 0000-0001-6323-4216

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Central nervous system (CNS) tumors consist of a diverse set of malignancies that remain clinically challenging due to their biological complexity, high morbidity, and limited responsiveness to current therapies. A growing body of genomic evidence has revealed that dysregulation of the mitogen-activated protein kinase (MAPK) signaling pathway is a recurrent and unifying characteristic across many pediatric and adult CNS tumor entities. Alterations affecting upstream receptor tyrosine kinases (RTKs), RAS GTPases, RAF kinases, and other associated regulators contribute to MAPK signaling pathway hyperactivation, shaping tumor behavior, therapy response and resistance. These aberrations ranging from hotspot mutations such as

Indexed as

BRAF-KIAA1549 fusionBRAF V600E mutationbrain tumorsMAPK signalingMEK inhibitorsRAF inhibitorsRAF-MEK-ERK pathwaytargeted therapy

Identifiers

PMID41514664
PMCPMC12785150

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.